Skip to main content
Premium Trial:

Request an Annual Quote

A 'Surge' of Cases

Premium

Because of current population growth trends, the number of cancer cases worldwide could go up to 22.2 million by the year 2030, a 75 percent increase from the 12.7 million worldwide cancer cases reported in 2008, says Miriam Falco at CNN's The Chart blog. According to a study in Lancet Oncology, a "surge" of cases is expected in developing countries, which are currently not ready to handle diagnosing, treating, or preventing the disease, Falco says. Freddie Bray of the International Agency for Research on Cancer and his colleagues looked at the variations in different types of cancer cases and deaths in countries with different levels of socio-economic development. They found that although there has been a decrease in infection-related cancers like stomach, liver, or cervical cancers in wealthier countries, that improvement is being outpaced by new cases in poorer countries associated with reproductive, dietary, or lifestyle factors like tobacco use, Falco adds.

The Scan

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.

Study Points to Synonymous Mutation Effects on E. Coli Enzyme Activity

Researchers in Nature Chemistry saw signs of enzyme activity shifts in the presence of synonymous mutations in a multiscale modeling analysis of three Escherichia coli genes.

Team Outlines Paternal Sample-Free Single-Gene Approach for Non-Invasive Prenatal Screening

With data for nearly 9,200 pregnant individuals, researchers in Genetics in Medicine demonstrate the feasibility of their carrier screening and reflex single-gene non-invasive prenatal screening approach.

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.